Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less
esmo - Findings from the POSEIDON meta-analysis of the MARCAP consortium
AI Summary: A pooled POSEIDON meta-analysis from the MARCAP consortium found that adding androgen-deprivation therapy to post‑operative radiotherapy for recurrent prostate cancer with PSA ≤0.5 ng/mL does not improve outcomes meaningfully. In short: the extra hormonal punch may not be worth the side effects many patients will endure.
Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61
Related Stories
Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128
Microplastics detected in most prostate cancer tumors, study finds / 3 months
Statins Rarely Cause Listed Side Effects, Review Confirms / 3 months
AHA25: Breakthroughs in Cardiovascular and Cardio‐Oncology / 6 months
FDA Greenlights Subcutaneous Daratumumab for Smoldering Multiple Myeloma / 6 months
Intellia CRISPR Trial Fatality Raises Safety Concerns / 6 months
Cancer Research UK campaign clears £250M milestone for research / 3 months
Household cats reveal human cancer gene parallels and treatment clues / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Medicaid, Neuroscience, Cancer Screening, Venture Capital and look for the RSS link.
StackHealth Time Machine